
    
      This is a master protocol designed to evaluate the safety, tolerability, and maximum
      tolerated dose (MTD) or recommended phase 2 dose (RP2D) and efficacy of AMG 160, in
      combination with enzalutamide, abiraterone, or the PD1 inhibitor AMG 404 as well as AMG 404
      monotherapy, in participants with metastatic castration-resistant prostate cancer (mCRPC).
    
  